semaglutide and tirzepatide. Tirzepatide key differences, weight loss results (2026) Semaglutide, tirzepatide recommended as first-line

Recent Industry Developments FDA Approval of Oral Wegovy and Orforglipron (Regulatory): On December 22, 2025, the FDA approved the first oral GLP-1 specifically for chronic weight management (the Wegovy pill), which launched in January 2026

It is usually administered as a subcutaneous injection once a week

- ALCAR HCl

Functional assessmentssuch as grip strength measurement, timed up-and-go tests, or chair stand testsprovide clinically meaningful data about muscle function and can identify patients requiring intervention

For anyone struggling with obesity or diabetes, seeking professional advice and guidance can help make an informed choice